Dynamic risk assessment is an important tool for healthcare providers to inform treatment selection and optimize patient outcomes. Frequent evaluation of clinical status provides invaluable information on adverse event risk and/or treatment urgency, based on the changes in predictive biomarkers. Landmark analysis is a useful approach for dynamic risk assessment that obviates the complexity of jointly modeling longitudinal covariates and time-to-event outcome. Traditional landmark methods often rely on the proportional hazards assumption and assume independent censoring. We propose novel methods to broaden the scope of landmark analysis by directly modeling the restricted residual mean survival time (RRMST) at each landmark date while accommodating dependent censoring. Advantages of RMST models include removing the assumption that the (hazard) model is correct at every time point; RMST models instead consider a single capped survival time. Moreover, investigators may prefer the area under the survival curve to the hazard function as a metric in terms of interpretability. We derive the asymptotic properties of our proposed estimators and validate their performance in finite samples through extensive simulations. We apply the proposed methods to analyze outcomes under natural end-stage liver disease (ESLD) history (i.e., in the absence of liver transplantation).
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: